1. Home
  2. EVO vs GERN Comparison

EVO vs GERN Comparison

Compare EVO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.76

Market Cap

895.8M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.72

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
GERN
Founded
1993
1990
Country
Germany
United States
Employees
4766
229
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
895.8M
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EVO
GERN
Price
$2.76
$1.72
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$7.00
$2.17
AVG Volume (30 Days)
106.1K
18.6M
Earning Date
04-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$0.21
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$1.04
52 Week High
$4.80
$2.01

Technical Indicators

Market Signals
Indicator
EVO
GERN
Relative Strength Index (RSI) 53.62 57.05
Support Level $2.32 $1.24
Resistance Level $3.75 $2.01
Average True Range (ATR) 0.08 0.10
MACD 0.07 0.03
Stochastic Oscillator 89.69 70.67

Price Performance

Historical Comparison
EVO
GERN

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: